IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 88-96

  Li, Ying Bo ^a   Wang, Zhong Qing ^a   Yan, Xu ^a   Chen, Mei Wan ^b   Bao, Jiao Lin ^b   Wu, Guo Sheng ^b   Ge, Ze Mei ^a   Zhou, De Min ^a   Wang, Yi Tao ^b   Li, Run Tao ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b University of Macau   (Macao)

Author keywords

Angiogenesis; Breast cancer; EGFR; Irreversible TKI

Indexed keywords

2 (BENZYLSULFINYL)ETHYL PYRIDIN 3 YLMETHYLCARBAMODITHIOATE; 2 CYANOETHYL PYRIDIN 3 YLMETHYLCARBAMODITHIOATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GAMMA HISTONE H2AX; HISTONE H2AX; IC 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; EMBRYO; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; TRANSGENIC ANIMAL; UMBILICAL VEIN ENDOTHELIAL CELL; ZEBRA FISH;

ANGIOGENESIS; BREAST CANCER; EGFR; IRREVERSIBLE TKI;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYO, NONMAMMALIAN; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; THIOCARBAMATES; ZEBRAFISH;

DANIO RERIO;

EID: 84883809887     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.005     Document Type: Article

References (35)

1. Saxena R., Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med. Res. Rev. 2012, 32:166-215.
2. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7:493-507.
3. Dedes K.J., Wetterskog D., Ashworth A., Kaye S.B., Reis-Filho J.S. Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 2011, 8:261-271.
4. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrnol. Rev. 1992, 13:3-17.
5. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in, 1029 patients with breast cancer. Breast Cancer Res. Treat. 2002, 71:67-75.
6. Doebele R.C., Oton A.B., Peled N., Camidge D.R., Bunn P.A. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 2010, 69:1-12.
7. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., Takigawa N., Takata M., Kiura K., Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007, 67:7807-7814.
8. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., Maehara Y., Yatabe Y., Mitsudomi T. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 2010, 16:5489-5498.
9. Li D., Shimamura T., Ji H., Chen L., Haringsma H.J., McNamara K., Liang M.C., Perera S.A., Zaghlul S., Borgman C.L., Kubo S., Takahashi M., Sun Y., Chirieac L.R., Padera R.F., Lindeman N.I., Janne P.A., Thomas R.K., Meyerson M.L., Eck M.J., Engelman J.A., Shapiro G.I., Wong K.K. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12:81-93.
10. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., Haber D.A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 2005, 102:7665-7670.
11. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandhi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.K., Janne P.A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67:11924-11932.
12. Kwak E. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist 2011, 16:1498-1507.
13. R.T. Li, Z.M. Ge, J.R. Cui, X.Y. Sun, Z.Q. Wang, X. Yan, Preparation of heteroaryl alkyl dithiocarbamate compounds as tyrosine kinase inhibitors, 2011 (Patent in China).
14. Garonna E., Botham K.M., Birdsey G.M., Randi A.M., Gonzalez-Perez R.R., Wheeler-Jones C.P. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One 2011, 6:e18823.
15. Lam H.W., Lin H.C., Lao S.C., Gao J.L., Hong S.J., Leong C.W., Yue P.Y., Kwan Y.W., Leung A.Y., Wang Y.T., Lee S.M. The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J. Cell Biochem. 2008, 103:195-211.
16. Chim S.M., Qin A., Tickner J., Pavlos N., Davey T., Wang H., Guo Y., Zheng M.H., Xu J. EGFL6 promotes endothelial cell migration and angiogenesis through the activation of ERK. J. Biol. Chem. 2011.
17. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64:6652-6659.
18. W. M., The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio), third ed. Eugene, 1995, pp. 385.
19. Milanezi F., Carvalho S., Schmitt F.C. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Exp. Rev. Mol. Diagn. 2008, 8:417-434.
20. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
21. Iivanainen E., Nelimarkka L., Elenius V., Heikkinen S.M., Junttila T.T., Sihombing L., Sundvall M., Maatta J.A., Laine V.J., Yla-Herttuala S., Higashiyama S., Alitalo K., Elenius K. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J. 2003, 17:1609-1621.
22. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., Abbruzzese J., Traxler P., Buchdunger E., Radinsky R., Fidler I.J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60:2926-2935.
23. Tang J.Y., Li S., Li Z.H., Zhang Z.J., Hu G., Cheang L.C., Alex D., Hoi M.P., Kwan Y.W., Chan S.W., Leung G.P., Lee S.M. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 2010, 5:e11822.
24. Ciardiello F., Caputo R., Borriello G., Del Bufalo D., Biroccio A., Zupi G., Bianco A.R., Tortora G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer 2002, 98:463-469.
25. Johnston S.R. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin. Breast Cancer 2009, 9(Suppl 1):S28-36.
26. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer J. 2010, 16:23-32.
27. Lobrich M., Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer 2007, 7:861-869.
28. Brugger W., Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment. Lung Cancer 2012.
29. Larsen A.K., Ouaret D., El Ouadrani K., Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 2011, 131:80-90.
30. Gotink K.J., Verheul H.M. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis 2010, 13:1-14.
31. Naumov G.N., Nilsson M.B., Cascone T., Briggs A., Straume O., Akslen L.A., Lifshits E., Byers L.A., Xu L., Wu H.K., Janne P., Kobayashi S., Halmos B., Tenen D., Tang X.M., Engelman J., Yeap B., Folkman J., Johnson B.E., Heymach J.V. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 2009, 15:3484-3494.
32. Lawson N.D., Weinstein B.M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 2002, 248:307-318.
33. Serbedzija G.N., Flynn E., Willett C.E. Zebrafish angiogenesis: a new model for drug screening. Angiogenesis 1999, 3:353-359.
34. Goldman C.K., Kim J., Wong W.L., King V., Brock T., Gillespie G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 1993, 4:121-133.
35. Moehler M., Frings C., Mueller A., Gockel I., Schimanski C.C., Biesterfeld S., Galle P.R., Holtmann M.H. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J. Gastroenterol. 2008, 14:4156-4167.